View clinical trials related to Stage III Melanoma.
Filter by:To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy.
This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.